<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02599324</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC-1128-CA</org_study_id>
    <nct_id>NCT02599324</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors</brief_title>
  <official_title>A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics LLC.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pharmacyclics LLC.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and efficacy of the
      combination treatment of ibrutinib with everolimus, paclitaxel, docetaxel, or cetuximab in
      selected advanced gastrointestinal and genitourinary tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1b: Determination of the recommended Phase 2 dose (RP2D) of ibrutinib in combination with everolimus in RCC, paclitaxel in urothelial carcinoma, docetaxel in gastric adenocarcinoma and cetuximab in CRC.</measure>
    <time_frame>Approximately 12 months after last patient enrolled</time_frame>
    <description>Evaluated by the number of dose-limiting toxicities (DLT) graded using the NCI CTCAE v 4.03</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Progression-free survival (PFS) of ibrutinib combination therapy in RCC and urothelial carcinoma</measure>
    <time_frame>Approximately 36 months after last patient enrolled.</time_frame>
    <description>Defined by the time from the date of first dose of study drug until confirmed disease progression based on investigator assessment, per RECIST 1.1, or death from any cause, whichever comes first</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: ORR of ibrutinib combination therapy in gastric adenocarcinoma and CRC</measure>
    <time_frame>Approximately 36 months after last patient enrolled.</time_frame>
    <description>Estimated using the All Treated Population as the proportion of subjects with a best response of complete response (CR) or partial response (PR) by investigator assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 2: PFS of ibrutinib combination therapy in gastric adenocarcinoma and CRC</measure>
    <time_frame>Approximately 36 months after last patient enrolled.</time_frame>
    <description>Defined by the time from the date of first dose of study drug until confirmed disease progression based on investigator assessment, per RECIST 1.1, or death from any cause, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: ORR of ibrutinib combination therapy in RCC and urothelial carcinoma</measure>
    <time_frame>Approximately 36 months after last patient enrolled.</time_frame>
    <description>Estimated using the All Treated Population as the proportion of subjects with a best response of complete response (CR) or partial response (PR) by investigator assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: DCR of ibrutinib combination therapy in each cohort</measure>
    <time_frame>Approximately 36 months after last patient enrolled.</time_frame>
    <description>Estimated using the All Treated Population as the proportion of subjects with a best response of CR, PR or stable disease (SD) of length greater than or equal to six weeks.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">261</enrollment>
  <condition>Renal Cell Carcinoma (RCC)</condition>
  <condition>Urothelial Carcinoma</condition>
  <condition>Gastric Adenocarcinoma</condition>
  <condition>Colorectal Adenocarcinoma (CRC)</condition>
  <arm_group>
    <arm_group_label>Phase 1b/2: Renal Cell Carcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1b: Patients will receive ibrutinib at various dose levels in combination with everolimus to determine the Recommended Phase 2 Dose (RP2D) of ibrutinib.
Phase 2: Patients will receive ibrutinib at the RP2D determined in Phase 1b in combination with everolimus.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b/2: Urothelial Carcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1b: Patients will receive ibrutinib at various dose levels in combination with paclitaxel to determine the RP2D of ibrutinib.
Phase 2: Subjects will receive paclitaxel at the RP2D determined in Phase 1b in combination with paclitaxel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b/2: Gastric Adenocarcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1b: Patients will receive ibrutinib at various dose levels in combination with docetaxel to determine the RP2D of ibrutinib.
Phase 2: Subjects will receive docetaxel at the RP2D determined in Phase 1b in combination with docetaxel.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b/2: Colorectal Adenocarcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1b: Patients will receive ibrutinib at various dose levels in combination with cetuximab to determine RP2D of ibrutinib.
Phase 2: Subjects will receive ibrutinib at the RP2D determined in Phase 1b in combination with cetuximab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibrutinib</intervention_name>
    <arm_group_label>Phase 1b/2: Renal Cell Carcinoma</arm_group_label>
    <arm_group_label>Phase 1b/2: Urothelial Carcinoma</arm_group_label>
    <arm_group_label>Phase 1b/2: Gastric Adenocarcinoma</arm_group_label>
    <arm_group_label>Phase 1b/2: Colorectal Adenocarcinoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
    <arm_group_label>Phase 1b/2: Renal Cell Carcinoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <arm_group_label>Phase 1b/2: Gastric Adenocarcinoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <arm_group_label>Phase 1b/2: Urothelial Carcinoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <arm_group_label>Phase 1b/2: Colorectal Adenocarcinoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  RCC (clear cell), urothelial carcinoma (transitional cell), gastric or
             gastro-esophageal junctional (GEJ) adenocarcinoma, or K-RAS or N-RAS wild-type EGFR
             expressing CRC

          -  For RCC:

               -  previously received at least 1 but no more than 4 lines of therapy, one therapy
                  must have included a VEGF TKI

               -  ECOG performance status of 0-1 (score of 2 may be acceptable)

          -  For urothelial carcinoma:

               -  previously received at least 1 but no more than 2 lines of therapy, one therapy
                  must have included a platinum based regimen

               -  ECOG performance status of 0-1

          -  For gastric or GEJ adenocarcinoma:

               -  previously received at least 1 but no more than 3 lines of therapy, one therapy
                  must have included a fluoropyrimidine based regimen

               -  ECOG performance status of 0-1

          -  For CRC:

               -  previously received at least 2 but no more than 4 lines of therapy, which must
                  have included both an irinotecan and an oxaliplatin based regimen

               -  ECOG performance status of 0-1 (score of 2 may be acceptable)

          -  For all cohorts:

               -  Adequate hematologic function:

                    -  Absolute neutrophil count (ANC) &gt;1500 cells/mm3

                    -  For RCC, platelet count ≥80,000 cells/mm3

                    -  For urothelial carcinoma, gastric or GEJ adenocarcinoma, and CRC, platelet
                       count ≥100,000 cells/mm3

                    -  For RCC, urothelial carcinoma, and gastric or GEJ adenocarcinoma, hemoglobin
                       ≥8.0 g/dL

                    -  For CRC, hemoglobin ≥9.0 g/dL

               -  Adequate hepatic and renal function defined as:

                    -  AST and/or ALT ≤5.0 x upper limit of normal (ULN) if liver metastases, or ≤3
                       x ULN without liver metastases

                    -  Alkaline phosphatase &lt;3.0 x ULN or ≤5.0 x ULN if liver or bone metastases
                       present

                    -  Bilirubin ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or
                       of non-hepatic origin, such as hemolysis)

                    -  Estimated Creatinine Clearance ≥30 mL/min

        Exclusion Criteria:

          -  For RCC, prior treatment with everolimus or temsirolimus

          -  For urothelial carcinoma, prior treatment with any taxane

          -  For gastric or GEJ adenocarcinoma, prior treatment with any taxane

          -  For CRC, prior treatment with cetuximab or panitumumab

          -  For all cohorts:

               -  concomitant use of warfarin or other Vitamin K antagonists

               -  history of stroke or intracranial hemorrhage within 6 months prior to enrollment

               -  major surgery within 4 weeks of first dose of study drug

               -  requires treatment with strong CYP3A inhibitors

               -  known bleeding disorders or hemophilia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Cole, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Pharmacyclics LLC.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bhagyashree Yadav</last_name>
    <phone>669-224-1104</phone>
    <email>byadav@pcyc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gurvinder Singh</last_name>
    <phone>669-224-1168</phone>
    <email>gsingh@pcyc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clearview Cancer Institute</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Avitra Bone</last_name>
      <phone>256-705-4283</phone>
      <email>avitrab@ccihsv.com</email>
    </contact>
    <investigator>
      <last_name>Paul S Dang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Palomino</last_name>
      <phone>858-822-2268</phone>
      <email>jepalomino@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>James M Randall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arlet Minassian</last_name>
      <phone>323-865-0802</phone>
      <email>Arlet.Minassian@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>David Quinn, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Mary's Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lonnie Leonard</last_name>
      <phone>415-750-4060</phone>
      <email>Lonnie.Leonard@DignityHealth.org</email>
    </contact>
    <investigator>
      <last_name>Robert W Weber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Nichols</last_name>
      <phone>310-633-8411</phone>
      <email>snichols@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Shenetra Walker</last_name>
      <phone>310-633-8411</phone>
      <email>skwalker@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lee Rosen, MA</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norwalk Hospital</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <zip>06856</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Long</last_name>
      <phone>203-845-2996</phone>
      <email>Jennifer.long@wchn.org</email>
    </contact>
    <investigator>
      <last_name>Richard Frank, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Montcalm</last_name>
      <phone>202-687-8974</phone>
      <email>jem257@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Pishvaian, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists, LLC, Department of Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenni Bachhofer</last_name>
      <phone>904-363-7462</phone>
      <phone_ext>1179</phone_ext>
      <email>Jenni.Bachhofer@CSNF.us</email>
    </contact>
    <contact_backup>
      <last_name>Judy Bulacan</last_name>
      <phone>904-264-6201</phone>
      <email>Judy.Bulacan@CSNF.us</email>
    </contact_backup>
    <investigator>
      <last_name>Mehdi M Moezi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Horizon Oncology Research, Inc</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheri Akridge</last_name>
      <phone>765-446-5111</phone>
      <email>sakridge@horizonbioadvance.com</email>
    </contact>
    <investigator>
      <last_name>Wael Harb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital Cancer Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jilliann De Jong</last_name>
      <phone>913-945-7539</phone>
      <email>jdejong@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen K Williamson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Jefferson General Hospital</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Guttierrez</last_name>
      <phone>504-503-5368</phone>
      <email>Nguttierrez@ejgh.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Cosgriff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leanne Ianniello</last_name>
      <phone>617-636-2883</phone>
      <email>LIanniello@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>Wasif W Saif, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DeQuindalyn Moore</last_name>
      <phone>313-576-9371</phone>
      <email>moored@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Ulka Vaishampayan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Mintoff</last_name>
      <phone>313-916-3721</phone>
      <email>SMINTOF1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Ding Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Mueller</last_name>
      <phone>402-354-7938</phone>
      <email>kimberly.mueller@nmhs.org</email>
    </contact>
    <investigator>
      <last_name>Ralph Hauke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer W Thomas</last_name>
      <phone>336-716-6914</phone>
      <email>jethomas@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>Boris Pasche, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Cancer Institute</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele St. Pierre</last_name>
      <phone>717-531-0003</phone>
      <phone_ext>28741</phone_ext>
      <email>astpierre@hmc.psu.edu</email>
    </contact>
    <investigator>
      <last_name>Nelson Yee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evan Bryant</last_name>
      <phone>215-662-7487</phone>
      <email>Evan.Bryant@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Glenda Rogers</last_name>
      <phone>215-662-7359</phone>
      <email>Glenda.Rodgers@uphs.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Peter O'Dwyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrina McClain</last_name>
      <phone>615-322-4967</phone>
      <email>katrina.mcclain@Vanderbilt.Edu</email>
    </contact>
    <investigator>
      <last_name>Jordan D Berlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas Medical Branch (UTMB) - Cancer Center</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nakia Watson</last_name>
      <phone>409-772-0575</phone>
      <email>nawatson@utmb.edu</email>
    </contact>
    <investigator>
      <last_name>Avi Markowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Memorial Hospital</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amit Nangrani</last_name>
      <phone>254-724-3796</phone>
      <email>Amit.Nangrani@BSWHealth.org</email>
    </contact>
    <investigator>
      <last_name>Lucas Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Choquette</last_name>
      <phone>703-280-5390</phone>
      <email>Karin.choquette@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Alex Spira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wenatchee Valley Hospital and Clinics</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98802</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Davis</last_name>
      <phone>509-664-4868</phone>
      <phone_ext>2046</phone_ext>
      <email>diane.m.davis@confluencehealth.org</email>
    </contact>
    <investigator>
      <last_name>Lindsay Overton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <state>Jeollanam-do</state>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Hyun Moon</last_name>
      <phone>82-61-379-8015</phone>
      <email>moonjh1207@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Ik Joo Chung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suyeon Lee</last_name>
      <phone>82-31-78708225</phone>
      <email>r1588@snubh.org</email>
    </contact>
    <investigator>
      <last_name>Keun-Wook Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hye Jung Park</last_name>
      <phone>82-2-2072-7613</phone>
      <email>ccrjung@naver.com</email>
    </contact>
    <investigator>
      <last_name>Do-Youn Oh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun Jung Park</last_name>
      <phone>+82 2 2228 8054</phone>
      <email>HJWWJD@yuhs.ac</email>
    </contact>
    <contact_backup>
      <last_name>Suji Jung</last_name>
      <phone>+82-2-2228-8058</phone>
      <email>SJJUNG@yuhs.ac</email>
    </contact_backup>
    <investigator>
      <last_name>Sang Joon Shin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meehwa Kim</last_name>
      <phone>82-2-3010-2259</phone>
      <email>crnonc6@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Sun Young Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seul Gi Lee</last_name>
      <phone>82-2-3410-3682</phone>
      <email>vitaminsg.lee@samsung.com</email>
    </contact>
    <investigator>
      <last_name>Young Suk Park</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sae-Young Kang</last_name>
      <phone>82-2-2626-2218</phone>
      <email>sezero79@naver.com</email>
    </contact>
    <investigator>
      <last_name>Sang Cheul Oh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla (HUMV)</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Zarrabeitia</last_name>
      <phone>(+34) 94 220 25 25</phone>
      <email>helenazp@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Fernando Rivera Herrero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluna</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Rodriguez</last_name>
      <phone>93 497 87 29</phone>
      <email>jrodriguez@igtp.cat</email>
    </contact>
    <investigator>
      <last_name>Laura Layos Romero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debora Moreno</last_name>
      <phone>(+34) 93 227 54 00</phone>
      <email>DMORENOF@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Joan Maurel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Blanco</last_name>
      <phone>(+34) 93 489 41 58</phone>
      <email>rblanco@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Maria Alsina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Barba</last_name>
      <phone>+34913368263</phone>
      <email>luis.barba@salud.madrid.org</email>
    </contact>
    <contact_backup>
      <last_name>Sara Lavin</last_name>
      <phone>+34913368263</phone>
      <email>slavin.hrc@salud.madrid.org</email>
    </contact_backup>
    <investigator>
      <last_name>Pablo Gajate Borau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger Solanas</last_name>
      <phone>+34 91 390 83 39</phone>
      <email>unidadc@h12o.es</email>
    </contact>
    <investigator>
      <last_name>Daniel Castellano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susana Feliu</last_name>
      <phone>34 91 727 75 16</phone>
      <email>susana.ft@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Melina Martin</last_name>
      <phone>34 91 727 75 16</phone>
      <email>ecmelina@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jaime Feliu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio (HUVR)</name>
      <address>
        <city>Seville</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Sabate</last_name>
      <phone>95 501 30 68</phone>
      <email>ana.sabate.garrachon@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Alejandro Falcon Gonzalez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Ferenova</last_name>
      <phone>0208 661 3637</phone>
      <email>Monika.Ferencova@rmh.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Nicola Evans</last_name>
      <email>Nicola.Evans@rmh.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Ian Chau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Glasgow - Institute of Cancer Sciences</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Fernon</last_name>
      <phone>44 (0) 141 301 7791</phone>
      <email>Laura.Fernon@glasgow.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Rob Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samatar Egueh</last_name>
      <phone>0203-219-5200</phone>
      <email>Samatar.Egueh@hcahealthcare.co.uk</email>
    </contact>
    <contact_backup>
      <last_name>Patrycja Szkatulska</last_name>
      <phone>0203-219-5200</phone>
      <email>Patrycja.Szkatulska@hcahealthcare.co.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Hendrik-Tobias Arkenau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Dewey</last_name>
      <phone>(0) 161 918 7883</phone>
      <email>Scott.Dewey@christie.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Amna Khwaja</last_name>
      <phone>(0) 161 918 7883</phone>
      <email>Amna.Khawaja@christie.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Francisca EM Marti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2015</study_first_submitted>
  <study_first_submitted_qc>November 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2015</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

